Navigation Links
Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats

Pristiq and placebo; whereas, the difference between active comparator and placebo was significant.

Additional Analyses

Additional analyses of key secondary endpoints from these three studies were also presented.

Effects of Desvenlafaxine on Sleep and Mood in Menopausal Women: A Pooled Analysis

This pooled analysis of two studies (Efficacy and Safety of Desvenlafaxine Succinate for Treatment of Menopausal Vasomotor Symptoms and Efficacy of Desvenlafaxine Succinate in the Treatment of Menopausal Vasomotor Symptoms) showed that Pristiq reduced the number of nighttime awakenings, increased the number of average minutes slept, and improved the quality of sleep score, compared with placebo. In addition, at the doses studied, Pristiq showed greater improvements from baseline in the Profile of Mood States (POMS) total mood score compared with placebo, with significant improvements in four out of six domains.

Sexual Function in Women Treated with Desvenlafaxine Succinate for Menopausal Vasomotor Symptoms

This secondary analysis of the 52-week trial (Efficacy and Safety of Desvenlafaxine Succinate for Treatment of Menopausal Vasomotor Symptoms) previously described showed that at week 12, women taking Pristiq did not experience a significant decrease in sexual function. This was measured by the Sex Effects Scale (Sex FX), a questionnaire developed to evaluate states and changes in sexual function in subjects taking antidepressant medications. Overall, there was a low incidence of sexual adverse events, and there was no statistical difference between Pristiq and placebo.

About Pristiq

Pristiq is a serotonin-norepinephrine reuptake inhibitor (SNRI) being studied by Wyeth as a potential treatment for multiple indications, including moderate-to-severe menopausal hot flashes and night sweats. Pristiq is believed to work by affecting the balance of serotonin and norepinephrine. These chemicals, known as neurotransmitters, are
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:7/22/2008)...s from a multi-center 293-patient European, trial...hange Symbol: CYT, MONTREAL, July 22 /PRNewswire-...obal leader in cryotherapy products to treat cardi...ously presented from three,European study centers ...,were published earlier today in the Journal of th...
(Date:7/22/2008)...s Development Plan Completed Successfully, DUBLIN...n Corporation,plc (NASDAQ: AMRN ) today announced...he U.S. Food and Drug Administration (FDA) to disc...treatment of,hypertriglyceridemia. Following these... with AMR101 in hypertriglyceridemia., Dr. Declan...
(Date:7/22/2008)...ntus(R) and Apidra(R) Resulted in Significant, Red...hatever the Algorithm .../ -- Results from the "Adjust to,Target in Type 2 ...ohydrate,Counting for Adjustment of Mealtime Insul...n Diabetes Association,s (ADA) medical journal,Di...
(Date:7/22/2008)...h chemotherapy and pegylated enzyme produces si...rapy alone - - Pegylated enzyme w...irstCall/ -- Halozyme Therapeutics,Inc. (Nasdaq: ...d,commercializing products targeting the extracell...ositive pre-clinical animal efficacy data,for its ...
Breaking Medicine Technology:CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5Whole Grains Do a Heart Good 4300 1Whole Grains Do a Heart Good 4300 2Whole Grains Do a Heart Good 4300 3Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 1Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 2Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 3Neptune Society Opens Tucson Arizona Office 4292 1Neptune Society Opens Tucson Arizona Office 4292 2Markel Expands Classes for Contagion Risk with OUTBREAK 28R 29 Extra Expense Coverage 4288 1Markel Expands Classes for Contagion Risk with OUTBREAK 28R 29 Extra Expense Coverage 4288 2
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Retina Group of New York will...ted macular degeneration especially designed for s...e Public Library at 116 Merritts Road, Farmingdale.... Attendance is free and refreshments will be prov...6) 939-6100. , Hicksville...
(Date:7/25/2008)... This donation will be used to fac...ve services for children , ... ( www.ivci.com ), a leading integrator of enterp...tion video conferencing, telepresence, audio visua...announced today that it has donated video conferen...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2
...ncer, such as radiotherapy, surgery and drugs as w...edical training// vary throughout the EU, accordin... Medical Oncology (ESMO) on 3 October 2006. Access...om country to country. The survey published in Me...
...ur of daily physical exercise for their future goo...agues at Glasgow University studied 545 children a...red the children who had the recommended adult lev...s, three times a week, reported the online edition...
...al health wards have been graded as unpleasant or ...atients//. The charity called Mind revealed that ...te of repair of their ward while 28% were not sati...Mind is for patients to be treated in a therapeuti...
...erts, some cancer patients are experiencing unjust...te of the new legislation to protect their rights/...fect from the end of last year has provided effect...h severe illnesses like cancer, multiple sclerosis...
Other Medicine News:Health News:Mental Health Wards rated unpleasant 2Health News:Injustice to cancer patients at work 2
Acetate Plate Sealers 100/Box
...croseal 'B' seals provide an adhesive-based sealin...tes. The aggressive adhesive layer ensures secure ...g, and tight sealing during thermal cycling when s...he perforated end-tabs can be removed when using t...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape.
Inquire
Medicine Products: